A Real-Time Urine Tenofovir Assay Improves Drug Adherence Among People With HIV With Prior Virologic Failure in a Randomized Controlled Trial
Clinical Infectious Diseases · 24.12.2025 · 81 (5) · e352-e359
DOI: 10.1093/cid/ciaf337 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 20.06.2025. Verfasst von Gert U van Zyl und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Virology, Department of Pathology, Stellenbosch University, Cape Town, South Africa. Hauptthemen laut MEDLINE: HIV Infections, Tenofovir, Anti-HIV Agents, Medication Adherence. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Collaborative Biomedical Research, NIAID NIH HHS.
Abstract (Originalsprache)
Background
Scalable strategies to detect and address inadequate adherence to antiretroviral therapy (ART) are a high priority towards meeting UNAIDS 95-95-95 targets. A urine tenofovir rapid assay (UTRA) at the point-of-care improves adherence among pre-exposure prophylaxis recipients and virologic suppression (VS) in a pre-post study of people with HIV (PWH). Here, we conducted the first randomized trial of UTRA-enhanced adherence support vs standard of care among PWH.
Methods
Participants receiving dolutegravir (DTG)– or protease inhibitor (PI)–based ART were randomized to UTRA-enhanced adherence support (n = 100) vs standard of care (n = 100). The primary outcome was VS, HIV-1 RNA <50 copies/mL, at 12-months and secondary outcome was VS at 6 months. To explore ART adherence over the preceding 6–8 weeks, tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) was quantified. C-reactive protein (CRP) was measured as an inflammatory marker.
Results
At the 12-month visit, 59/80 (74%) in the intervention and 48/75 (64%) in the control arm achieved VS (the same proportion as at 6 months; P = .2); TFV-DP concentrations (median, IQR) in DBS were significantly higher in the intervention arm: 884 (491–1296) vs 598 (239–964) fmol/3-mm DBS punch in the control arm (P < .01). Higher TFV-DP DBS concentrations correlated with a slight decrease in CRP (Spearman's rho = −0.19; P = .02).
Conclusions
UTRA-enhanced adherence support did not result in a significantly higher VS rate but was associated with increased TFV-DP in DBS—in turn, associated with lower CRP levels—suggesting that UTRA-enhanced adherence support improves long-term drug exposure and could also reduce HIV-associated inflammation. Clinical Trials Registration clinicaltrials.gov (https://clinicaltrials.gov/study/NCT05333679).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Virology, Department of Pathology, Stellenbosch University, Cape Town, South Africa.
- National Health Laboratory Service, Tygerberg, Cape Town, South Africa.
- Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University, Cape Town, South Africa.
- Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town, South Africa.
- Division of Infectious Diseases, Department of Medicine, Stellenbosch University, Cape Town, South Africa.
- Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, UCSF/San Francisco General Hospital, San Francisco, California, USA.
ORCID-Profile: Gert U van Zyl, Eric Decloedt, Lauren Jennings, Tracy Kellermann, Khethiwe Motha, Marije van Schalkwyk, Chantel Schreuder, Nicola Coetzee, David V Glidden, Catherine Orrell, Monica Gandhi
Förderung
- NIH HHS
- Collaborative Biomedical Research
- NIAID NIH HHS
- NIAID
- US National Institutes of Health (NIH) and South African Medical Research Council
- NIH
Zitieren
APA
van Zyl, G. U., Decloedt, E., Jennings, L., Kellermann, T., Motha, K., van Schalkwyk, M., Schreuder, C., Coetzee, N., Glidden, D. V., Orrell, C., & Gandhi, M. (2025). A Real-Time Urine Tenofovir Assay Improves Drug Adherence Among People With HIV With Prior Virologic Failure in a Randomized Controlled Trial. Clinical Infectious Diseases, 81(5), e352-e359. https://doi.org/10.1093/cid/ciaf337
Vancouver
van Zyl GU, Decloedt E, Jennings L, Kellermann T, Motha K, van Schalkwyk M, et al. A Real-Time Urine Tenofovir Assay Improves Drug Adherence Among People With HIV With Prior Virologic Failure in a Randomized Controlled Trial. Clinical Infectious Diseases. 2025;81(5):e352-e359. doi:10.1093/cid/ciaf337
BibTeX
@article{vanZyl2025,
author = {van Zyl, Gert U and Decloedt, Eric and Jennings, Lauren and Kellermann, Tracy and Motha, Khethiwe and van Schalkwyk, Marije and Schreuder, Chantel and Coetzee, Nicola and Glidden, David V and Orrell, Catherine and Gandhi, Monica},
title = {A Real-Time Urine Tenofovir Assay Improves Drug Adherence Among People With HIV With Prior Virologic Failure in a Randomized Controlled Trial},
journal = {Clinical Infectious Diseases},
year = {2025},
volume = {81},
number = {5},
pages = {e352--e359},
doi = {10.1093/cid/ciaf337}
}
EUVIMED